Zheng Li, Gan Li-Hong, Yao Ling, Li Bin, Huang Ya-Qin, Zhang Fu-Bao, Kuang Meng-Qi, Fang Nian
Department of Gastroenterology, The First Hospital of Nanchang, Nanchang 330008, Jiangxi Province, China.
Department of Stomatology, The First Hospital of Nanchang, Nanchang 330008, Jiangxi Province, China.
World J Clin Cases. 2023 Sep 16;11(26):6083-6090. doi: 10.12998/wjcc.v11.i26.6083.
The incidence and mortality rates of gastric cancer in China are the second-highest in the world, and most patients with gastric cancer lose their chance of surgery by the time of their diagnosis.
To explore the predictive potential of serum basic fibroblast growth factor and interleukin-1β levels for the effect of first-line chemotherapy in patients with advanced gastric cancer.
From the gastric cancer patients admitted to our hospital from May 2019 to April 2023, 84 patients were selected and randomly and equally assigned to the experimental or control group. The FLOT group received the FLOT chemotherapy regimen (composed of oxaliplatin + calcium folinate + fluorouracil + paclitaxel), while the SOX group received the SOX chemotherapy regimen (composed of oxaliplatin + tiga capsules). The clinical efficacy, tumor marker levels, adverse reactions, and survival rates of the two groups were compared 7 days after the end of the relevant treatments.
The target effective rate of the FLOT group was 54.76%, which was much higher than that of the SOX group (33.33%; < 0.05). After treatment, both the groups demonstrated lower levels of cancer antigen (CEA), carbohydrate antigen 199 (CA199), and peptide tissue antigen (TPS). For several patients before treatment ( < 0.05). Third and fourth grades. In terms of adverse reactions, the level of white blood cells in both the groups was lower. Moreover, the incidence of hand-foot skin reactions in these two study groups was lower ( < 0.05), while those of peripheral neuritis, vomiting, diarrhea, and abnormal liver function were significant ( < 0.05). No statistically significant difference was noted between the two groups ( < 0.05). The 1-year survival rate was higher in the FLOT group ( < 0.05).
The FLOT regimen was effective in reducing the serum CEA, CA199, and TPS levels as well as in improving the 1-year survival rate of patients with good tolerability, making it worthy of clinical promotion and application.
中国胃癌的发病率和死亡率位居世界第二，大多数胃癌患者在确诊时就已失去手术机会。
探讨血清碱性成纤维细胞生长因子和白细胞介素-1β水平对晚期胃癌患者一线化疗疗效的预测潜力。
选取2019年5月至2023年4月我院收治的胃癌患者84例，随机等分为试验组和对照组。FLOT组接受FLOT化疗方案（由奥沙利铂+亚叶酸钙+氟尿嘧啶+紫杉醇组成），而SOX组接受SOX化疗方案（由奥沙利铂+替吉奥胶囊组成）。在相关治疗结束7天后比较两组的临床疗效、肿瘤标志物水平、不良反应和生存率。
FLOT组的目标有效率为54.76%，远高于SOX组（33.33%；P<0.05）。治疗后，两组的癌胚抗原（CEA）、糖类抗原199（CA199）和肽组织抗原（TPS）水平均降低。治疗前部分患者（P<0.05）。三、四级。在不良反应方面，两组的白细胞水平均降低。此外，这两个研究组的手足皮肤反应发生率较低（P<0.05），而周围神经炎、呕吐、腹泻和肝功能异常的发生率较高（P<0.05）。两组之间无统计学显著差异（P<0.05）。FLOT组的1年生存率较高（P<0.05）。
FLOT方案在降低血清CEA、CA199和TPS水平以及提高患者1年生存率方面有效，耐受性良好，值得临床推广应用。
